TY - JOUR
T1 - Effect of methandrostenolone on postmenopausal bone wasting as assessed by changes in total bone mineral mass
AU - Chesnut, Charles H.
AU - Nelp, Wil B.
AU - Baylink, David J.
AU - Denney, John D.
N1 - Funding Information:
From the Division of Nuclear Medicine, Deparrments of Medicine and Radiology, University of Washington School of Medicine. and the Mineral Melabolism Laboratories, Departments of Medicine, Veterans Administration Hospital, Seattle, Wash. Received for publication October 29, 1975. Supported in part by Atomic Energy Commission Grant A T(45-I)-2225 and USPHS Grams I FO3 AM53150-01 and HD 04872. Dr. Chesnur is the recipient of a Picker Scholar Award: Dr. Baylink is the recipient of Research Career Development A ward DE 19108. Presented in part at the American Federation for Clinical Research. Atlantic City, New Jersey, Ma,v 5, 1974. Reprinr requests should be addressed IO Dr. Chesnut at rhe Division of Nuclear Medicine, University of Washingron School of Medicine, Seattle, Washingron 98195. D I977 by Grune & Stratton. Inc.
PY - 1977/3
Y1 - 1977/3
N2 - To assess the efficacy of methandrostenolone in the treatment of osteoporosis a 26-mo double-blind study was performed with 13 treated and 13 control (placebo) postmenopausal osteoporotic females. Drug effect was assessed primarily by determinations of total body calcium (TBC) by neutron activation analysis, essentially a measurement of total bone mineral mass. Results in the 16 patients completing the study (10 treated and 6 placebo), as well as in all 26 patients participating in the study, showed significant (p < 0.01) differences in the change in TBC between treated and control groups. In patients dropping out, TBC changes through the time of dropout were similar to those in patients completing the study. In those patients completing the study, TBC increased 2% in the treated group and decreased 3% in the placebo group. An approximate sixfold difference in extraskeletal calcium balance would be required to explain the magnitude of the observed intergroup TBC difference. The drug effect appeared to persist throughout the 26-mo observation period. Thus these data strongly suggest that long-term use of methandrostenolone in postmenopausal osteoporosis prevented bone loss; the possibility that it increased bone mass above initial values is less certain.
AB - To assess the efficacy of methandrostenolone in the treatment of osteoporosis a 26-mo double-blind study was performed with 13 treated and 13 control (placebo) postmenopausal osteoporotic females. Drug effect was assessed primarily by determinations of total body calcium (TBC) by neutron activation analysis, essentially a measurement of total bone mineral mass. Results in the 16 patients completing the study (10 treated and 6 placebo), as well as in all 26 patients participating in the study, showed significant (p < 0.01) differences in the change in TBC between treated and control groups. In patients dropping out, TBC changes through the time of dropout were similar to those in patients completing the study. In those patients completing the study, TBC increased 2% in the treated group and decreased 3% in the placebo group. An approximate sixfold difference in extraskeletal calcium balance would be required to explain the magnitude of the observed intergroup TBC difference. The drug effect appeared to persist throughout the 26-mo observation period. Thus these data strongly suggest that long-term use of methandrostenolone in postmenopausal osteoporosis prevented bone loss; the possibility that it increased bone mass above initial values is less certain.
UR - https://www.scopus.com/pages/publications/0017348685
UR - https://www.scopus.com/pages/publications/0017348685#tab=citedBy
U2 - 10.1016/0026-0495(77)90073-7
DO - 10.1016/0026-0495(77)90073-7
M3 - Article
C2 - 319322
SN - 0026-0495
VL - 26
SP - 267
EP - 277
JO - Metabolism
JF - Metabolism
IS - 3
ER -